Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016, Article ID 2940496, 7 pages
http://dx.doi.org/10.1155/2016/2940496
Research Article

Uroplakin II Expression in Breast Carcinomas Showing Apocrine Differentiation: Putting Some Emphasis on Invasive Pleomorphic Lobular Carcinoma as a Potential Mimic of Urothelial Carcinoma at Metastatic Sites

Department of Pathology, Fujieda Municipal General Hospital, Shizuoka 426-8677, Japan

Received 4 January 2016; Accepted 9 May 2016

Academic Editor: Valeria Barresi

Copyright © 2016 Shogo Tajima and Kenji Koda. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. L. Hoang, D. E. Tacha, W. Qi et al., “A newly developed uroplakin ii antibody with increased sensitivity in urothelial carcinoma of the bladder,” Archives of Pathology and Laboratory Medicine, vol. 138, no. 7, pp. 943–949, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Z. Clark, S. Beriwal, D. J. Dabbs, and R. Bhargava, “Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas,” American Journal of Clinical Pathology, vol. 142, no. 1, pp. 64–71, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Tian, G. Guner, H. Miyamoto et al., “Utility of uroplakin II expression as a marker of urothelial carcinoma,” Human Pathology, vol. 46, pp. 58–64, 2015. View at Google Scholar
  4. L. L. Hoang, D. Tacha, R. E. Bremer, T. S. Haas, and L. Cheng, “Uroplakin II (UPII), GATA3, and p40 are highly sensitive markers for the differential diagnosis of invasive urothelial carcinoma,” Applied Immunohistochemistry and Molecular Morphology, vol. 23, no. 10, pp. 711–716, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. G. P. Paner, C. Annaiah, C. Gulmann et al., “Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder,” Human Pathology, vol. 45, no. 7, pp. 1473–1482, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Butler and M. Rosa, “Pleomorphic lobular carcinoma of the breast: a morphologically and clinically distinct variant of lobular carcinoma,” Archives of Pathology and Laboratory Medicine, vol. 137, no. 11, pp. 1688–1692, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Eusebi, F. Magalhaes, and J. G. Azzopardi, “Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation,” Human Pathology, vol. 23, no. 6, pp. 655–662, 1992. View at Publisher · View at Google Scholar · View at Scopus
  8. J. S. Bentz, N. Yassa, and F. Clayton, “Pleomorphic lobular carcinoma of the breast: clinicopathologic features of 12 cases,” Modern Pathology, vol. 11, no. 9, pp. 814–822, 1998. View at Google Scholar · View at Scopus
  9. A.-C. Vargas, S. R. Lakhani, and P. T. Simpson, “Pleomorphic lobular carcinoma of the breast: molecular pathology and clinical impact,” Future Oncology, vol. 5, no. 2, pp. 233–243, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Jacobs, F. Fan, and O. Tawfik, “Clinicopathologic and biomarker analysis of invasive pleomorphic lobular carcinoma as compared with invasive classic lobular carcinoma: an experience in our institution and review of the literature,” Annals of Diagnostic Pathology, vol. 16, no. 3, pp. 185–189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. X.-R. Wu, X.-P. Kong, A. Pellicer, G. Kreibich, and T.-T. Sun, “Uroplakins in urothelial biology, function, and disease,” Kidney International, vol. 75, no. 11, pp. 1153–1165, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Mazoujian, G. S. Pinkus, S. Davis, and D. E. Haagensen Jr., “Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features,” American Journal of Pathology, vol. 110, no. 2, pp. 105–112, 1983. View at Google Scholar · View at Scopus
  13. W. Sun and G. A. Herrera, “E-cadherin expression in invasive urothelial carcinoma,” Annals of Diagnostic Pathology, vol. 8, no. 1, pp. 17–22, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Longatto Filho, H. Bisi, V. A. F. Alves et al., “Adenocarcinoma in females detected in serous effusions: cytomorphologic aspects and immunocytochemical reactivity to cytokeratins 7 and 20,” Acta Cytologica, vol. 41, no. 4, pp. 961–971, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Tot, “Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma,” European Journal of Cancer, vol. 38, no. 6, pp. 758–763, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. S. K. Mohanty, S. C. Smith, E. Chang et al., “Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas,” American Journal of Clinical Pathology, vol. 142, no. 2, pp. 173–183, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. S. C. Smith, S. K. Mohanty, L. P. Kunju et al., “Uroplakin II outperforms uroplakin III in diagnostically challenging settings,” Histopathology, vol. 65, no. 1, pp. 132–138, 2014. View at Publisher · View at Google Scholar · View at Scopus